An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

ConclusionApalutamide had manageable safety profile, without any DLT or any new safety signals, and favourable efficacy in Japanese mCRPC patients. Thus, it was ascertained to be an adequate dosage regimen in Japanese mCRPC patients.Trial registrationClinicalTrials.gov identifier: NCT02162836.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research